{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:57:34Z","timestamp":1776329854130,"version":"3.50.1"},"reference-count":15,"publisher":"Baskent University","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.6002\/ect.2024.0182","type":"journal-issue","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T06:53:31Z","timestamp":1728975211000},"source":"Crossref","is-referenced-by-count":1,"title":[],"prefix":"10.6002","volume":"22","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Darmon M, Canet E, Ostermann M. Ten tips to manage renal transplant recipients. Intensive Care Med. 2019;45(3):380-383. doi:10.1007\/s00134-018-05509-6","DOI":"10.1007\/s00134-018-05509-6"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Brodsky SV, Satoskar A, Chen J, et al. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis. 2009;54(6):1121-1126. doi:10.1053\/j.ajkd.2009.04.024","DOI":"10.1053\/j.ajkd.2009.04.024"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. de Aquino Moura KB, Behrens PMP, Pirolli R, et al. Anticoagulant-related nephropathy: systematic review and meta-analysis. Clin Kidney J. 2019;12(3):400-407. doi:10.1093\/ckj\/sfy133","DOI":"10.1093\/ckj\/sfy133"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Tennekoon HD, Kousios A, Gardiner R, et al. Anticoagulant-related nephropathy in a renal transplant recipient. Kidney Int Rep. 2020;5(11):2089-2096. doi:10.1016\/j.ekir.2020.08.005","DOI":"10.1016\/j.ekir.2020.08.005"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Golbin L, Vigneau C, Touchard G, et al. Warfarin-related nephropathy induced by three different vitamin K antagonists: analysis of 13 biopsy-proven cases. Clin Kidney J. 2017;10(3):381-388. doi:10.1093\/ckj\/sfw133","DOI":"10.1093\/ckj\/sfw133"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Brodsky SV, Satoskar A, Hemminger J, et al. Anticoagulant-related nephropathy in kidney biopsy: a single-center report of 41 cases. Kidney Med. 2019;1(2):51-56. doi:10.1016\/j.xkme.2019.03.002","DOI":"10.1016\/j.xkme.2019.03.002"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Fujino Y, Takahashi C, Mitsumoto K, Uzu T. Rivaroxaban-related acute kidney injury in a patient with IgA vasculitis. BMJ Case Rep. 2019;12(1):e227756. doi:10.1136\/bcr-2018-227756.","DOI":"10.1136\/bcr-2018-227756"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Escoli R, Santos P, Andrade S, Carvalho F. Dabigatran-related nephropathy in a patient with undiagnosed IgA nephropathy. Case Rep Nephrol. 2015;2015:298261. doi:10.1155\/2015\/298261","DOI":"10.1155\/2015\/298261"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Brodsky S, Eikelboom J, Hebert LA. Anticoagulant-related nephropathy. J Am Soc Nephrol. 2018;29(12):2787-2793. doi:10.1681\/ASN.2018070741","DOI":"10.1681\/ASN.2018070741"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011;80(2):181-189. doi:10.1038\/ki.2011.44","DOI":"10.1038\/ki.2011.44"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Lim AKH, Campbell DA. Haematuria and acute kidney injury in elderly patients admitted to hospital with supratherapeutic warfarin anticoagulation. Int Urol Nephrol. 2013;45(2):561-570. doi:10.1007\/s11255-012-0364-0","DOI":"10.1007\/s11255-012-0364-0"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Brodsky SV, Collins M, Park E, et al. Warfarin therapy that results in an international normalization ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract. 2010;115(2):c142-c146. doi:10.1159\/000312877","DOI":"10.1159\/000312877"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Trujillo H, Sandino J, Cavero T, et al. IgA nephropathy is the most common underlying disease in patients with anticoagulant-related nephropathy. Kidney Int Rep. 2022;7(4):831-840. doi:10.1016\/j.ekir.2022.01.1048","DOI":"10.1016\/j.ekir.2022.01.1048"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. L'Imperio V, Guarnieri A, Pieruzzi F, Sinico RA, Pagni F. Anticoagulant-related nephropathy: a pathological note. J Thromb Thrombolys. 2018;46(2):260-263. doi:10.1007\/s11239-018-1669-3","DOI":"10.1007\/s11239-018-1669-3"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Dasgupta A, Mikhalina G, Satoskar AA, et al. Clinical outcomes in patients with biopsy proven anticoagulant-related nephropathy. Kidney Int Rep. 2023;8(7):1445-1448. doi:10.1016\/j.ekir.2023.04.014","DOI":"10.1016\/j.ekir.2023.04.014"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T10:39:08Z","timestamp":1728988748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/archive\/2024\/22\/9\/0\/717\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2024.0182","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}